Cigarette smoke-induced oxidative stress in COPD
Hoffmann, Roland Frederik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
CHAPTER 3

Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD

Anta Ngkelo*, Roland F Hoffmann*, Andrew L Durham, John A Marwick, Simone M Brandenburg, Harold G de Bruin, Marnix R Jonker, Eleni Tsitsiou, Gaetano Caramori, Marco Contoli, Paolo Casolari, Francesco Monaco, Filippo Andò, Giuseppe Speciale, Iain Kilty, Kian F Chung, Alberto Papi, Mark A Lindsay, Nick HT ten Hacken, Maarten van den Berge, Wim Timens, Peter J Barnes Antoon J van Oosterhout, Ian M Adcock*, Paul A Kirkham*, Irene H Heijink*

*These authors contributed equally to this work

Ngkelo, Hoffmann et al. AJP-lung. 2015
Abstract

In Chronic Obstructive Pulmonary Disease (COPD), oxidative stress regulates the inflammatory response of bronchial epithelium and monocytes/macrophages through kinase modulation and has been linked to glucocorticoid unresponsiveness. GSK3β inactivation plays a key role in mediating signalling processes upon reactive oxygen species (ROS) exposure. We hypothesized that GSK3β is involved in oxidative stress-induced glucocorticoid insensitivity in COPD. We studied levels of p-GSK3β-ser9, a marker of GSK3β inactivation, in lung sections and cultured monocytes and bronchial epithelial cells of COPD patients, control smokers and non-smokers. We observed increased levels of p-GSK3β-ser9 in monocytes, alveolar macrophages and bronchial epithelial cells from COPD patients and control smokers compared to non-smokers. Pharmacological inactivation of GSK3β did not affect CXCL8 or GM-CSF expression but resulted in glucocorticoid insensitivity in vitro in both inflammatory and structural cells. Further mechanistic studies in monocyte and bronchial epithelial cell lines showed that GSK3β inactivation is a common effector of oxidative stress induced activation of the MEK/ERK-1/2 and PI3K/Akt signalling pathways leading to glucocorticoid unresponsiveness. In primary monocytes, the mechanism involved modulation of histone deacetylase 2 (HDAC2) activity in response to GSK3β inactivation. In conclusion, we demonstrate for the first time that ROS-induced glucocorticoid unresponsiveness in COPD is mediated through GSK3β, acting as a ROS-sensitive hub.
Introduction

COPD is characterized by chronic lung inflammation, airway remodelling and pulmonary emphysema, which leads to airflow limitation and accelerated lung function decline. Current therapies fail to prevent either disease progression or mortality. Glucocorticoids are widely used because of their broad anti-inflammatory effects, but they provide relatively little therapeutic benefit in COPD (3). The reduced responsiveness to the anti-inflammatory effects of glucocorticoids is a major barrier to effective management of COPD patients. Therefore, there is an urgent need to understand the underlying molecular mechanisms. The increased oxidant burden in the lungs of COPD patients, derived from cigarette smoke (CS) and the respiratory burst from inflammatory cells, plays a significant role in the reduced glucocorticoid responsiveness (4, 10, 25, 33, 41). Oxidative stress has a profound impact on inflammation by inducing pro-inflammatory mediators that attract and activate neutrophils, including CXCL8 and GM-CSF. This induction is driven by activation of redox sensitive kinase pathways (including MAPK and PI3K/Akt signalling) and pro-inflammatory transcription factors such as the nuclear factor-κB (NF-κB) (8, 26, 27, 31, 32, 37). In addition, oxidative stress can induce PI3K-dependent post-translational histone deacetylase 2 (HDAC2) modifications, including phosphorylation, resulting in proteasomal HDAC2 degradation (1, 22, 27, 33). HDAC2 can deacetylate the glucocorticoid receptor (GRα) as well as histones at NF-κB response elements within promoter regions of inflammatory genes (21–23). Reduced HDAC2 expression has been observed in the lungs and alveolar macrophages of COPD patients and has been implicated in glucocorticoid insensitivity in COPD (22, 23). In addition to alveolar macrophages, we recently observed that bronchial epithelial cells from COPD patients are less responsive to glucocorticoids than those from healthy controls (16). Here, pro-inflammatory cytokine production was effectively suppressed by glucocorticoids in cells from healthy controls, while this response was compromised in COPD-derived cells. The constitutively active serine/threonine kinase glycogen synthase 3β (GSK3β) is regulated by oxidative stress and has been linked to several inflammatory diseases (6, 20, 24). GSK3β activity is negatively regulated by phosphorylation on serine 9, which can be mediated by ERK1/2 MAPK and Akt (15). As these kinase pathways are commonly involved in oxidant-mediated responses, GSK3β may represent an important downstream effector of oxidant-mediated signalling during COPD inflammation. We hypothesized that GSK3β is involved in oxidative stress-induced glucocorticoid responsiveness in COPD. We demonstrate that levels of inactive GSK3β are enhanced in monocytes, macrophages and bronchial epithelial cells from COPD patients compared to smokers and non-smokers, and that oxidative stress-induced GSK3β inhibition regulates glucocorticoid responsiveness in both monocytes/macrophages and bronchial epithelial cells.
Methods

Human studies

Peripheral lung sections, peripheral venous blood, primary bronchial epithelial cells (PBECs) and tissue sections were isolated from age-matched non-smokers, smokers with normal lung function and COPD patients. For GSK3β phosphorylation and total staining analysis, peripheral lung sections were collected from 21 patients with COPD, 19 smokers, and 14 non-smokers subjects (Table 1) and from 12 COPD patients, 12 smokers and 10 non-smokers (Table 2) respectively. Phospho-GSK3β was also detected in tissue macrophages of severe COPD patients (Table 1). Peripheral venous blood was collected from 10 patients with COPD, 6 smokers with normal lung function and 7 non-smokers (Table 3). Primary bronchial epithelial cells (PBECs) were obtained from 14 current and ex-smoking COPD patients with GOLD stage II-IV, 16 age-matched control smokers and 14 non-smokers (Table 4)(17). With the exception of the COPD stage IV patients, subjects did not use ICS, long-acting β-agonists and long-acting anticholinergics for at least 4 weeks preceding the study. The study protocol for this part was consistent with the Research Code of the University Medical Center Groningen (http://www.rug.nl/umcg/onderzoek/researchcode/index) and national ethical and professional guidelines (“Code of conduct; Dutch federation of biomedical scientific societies”; http://www.federa.org).

Table 1. Characteristics of subjects for the immunohistochemical study of phospho-GSK3β

<table>
<thead>
<tr>
<th></th>
<th>Non-Smokers</th>
<th>Smokers</th>
<th>COPD</th>
<th>Severe COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>67.7±8.1</td>
<td>70.0±6.7</td>
<td>69.1±6.6</td>
<td>70.3±2.8</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>0/14</td>
<td>18/1</td>
<td>18/3</td>
<td>7/0</td>
</tr>
<tr>
<td>Current/former smokers</td>
<td>N/A</td>
<td>9/10</td>
<td>7/14</td>
<td>3/4</td>
</tr>
<tr>
<td>Pack years</td>
<td>N/A</td>
<td>49.4±32.3</td>
<td>40.5±20.1</td>
<td>50.6±11.6</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>2.1±0.4</td>
<td>2.5±0.7</td>
<td>2.03±0.5</td>
<td>1.13±0.073</td>
</tr>
<tr>
<td>FEV1 (% pred)</td>
<td>101.5±22.5</td>
<td>91.8±14.6</td>
<td>75.3±16.6</td>
<td>41.3±3.0</td>
</tr>
<tr>
<td>FEV1/FVC Ratio (%)</td>
<td>76.4±3.5</td>
<td>75.5±4.6</td>
<td>56.1±9.1</td>
<td>51.7±4.9</td>
</tr>
<tr>
<td>GOLD Stage</td>
<td>N/A</td>
<td>N/A</td>
<td>8 grade 1,</td>
<td>All grade 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>11 grade 2,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 grade 3</td>
<td></td>
</tr>
</tbody>
</table>

Peripheral lung tissue sections were collected from patients recruited from the Section of Respiratory Diseases of the University Hospital of Ferrara. Data are presented as means ± SDs; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity. The FEV1/FVC ratio is after bronchodilator for subjects with COPD but not for smokers or non-smokers; GOLD, Global Initiative for Chronic Obstructive Lung Disease guideline classification of patients with COPD; % pred: % predicted; M: Male; F: Female.
Effect of GSK3β on glucocorticoid function in COPD

Table 2. Characteristics of subjects for the immunohistochemical study of total GS3Kβ

<table>
<thead>
<tr>
<th></th>
<th>Non-smokers</th>
<th>Control smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>69.1 ±2.5</td>
<td>65.4 ±1.9</td>
<td>69.5±2.1</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>2/8</td>
<td>12/0</td>
<td>12/0</td>
</tr>
<tr>
<td>Current/former smokers</td>
<td>N/A</td>
<td>6/6</td>
<td>7/5</td>
</tr>
<tr>
<td>Pack-years</td>
<td>N/A</td>
<td>49.1±12.1</td>
<td>37.9±3.3</td>
</tr>
<tr>
<td>FEV₁ (% pred)</td>
<td>111.2±6.2</td>
<td>90.5±4.8</td>
<td>70.4±3.8</td>
</tr>
<tr>
<td>FEV₁/FVC ratio (%)</td>
<td>78.1±1.4</td>
<td>76.8±1.2</td>
<td>59.4±2.1</td>
</tr>
</tbody>
</table>

Peripheral lung tissue sections were collected from patients recruited from the Section of Respiratory Diseases of the University Hospital of Ferrara. Data are presented as means ± SDs; FEV₁: Forced expiratory volume in one second; FVC: Forced vital capacity. The FEV₁/FVC ratio is after bronchodilator for subjects with COPD but not for smokers or non-smokers; % pred: % predicted; M: Male, F: Female.

Table 3. Characteristics of subjects: peripheral blood monocytes

<table>
<thead>
<tr>
<th></th>
<th>Non-Smokers</th>
<th>Controls smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57 ± 4.4</td>
<td>55.5 ± 3.2</td>
<td>65.6 ± 4.4</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>3/4</td>
<td>4/2</td>
<td>8/2</td>
</tr>
<tr>
<td>Current/former smokers</td>
<td>N/A</td>
<td>5/1</td>
<td>2/8</td>
</tr>
<tr>
<td>Pack years</td>
<td>N/A</td>
<td>31 ± 12.3</td>
<td>33.1 ± 14.2</td>
</tr>
<tr>
<td>FEV₁ (% pred)</td>
<td>105.6 ± 7.5</td>
<td>92.2 ± 14.5</td>
<td>68.65 ± 16</td>
</tr>
<tr>
<td>FEV₁/FVC Ratio</td>
<td>72.54 ± 3.9</td>
<td>73.02 ± 8.8</td>
<td>58.79 ± 15.7</td>
</tr>
</tbody>
</table>

Peripheral venous blood was collected from patients at the Royal Brompton hospital of London. Data are presented as means ± SD; FEV₁: Forced expiratory volume in one second; FVC: Forced vital capacity. The FEV₁/FVC ratio is after bronchodilator for subjects with COPD but not for smokers or non-smokers; % pred: % predicted. M: Male, F: Female.

Table 4. Characteristics of the subjects: primary bronchial epithelial cells (PBECs)

<table>
<thead>
<tr>
<th></th>
<th>Non-Smokers</th>
<th>Control smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>56 (43-76)</td>
<td>54 (43-70)</td>
<td>56.5(50-65)</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>5/6</td>
<td>9/3</td>
<td>4/4</td>
</tr>
<tr>
<td>Pack years</td>
<td>0(0-0)</td>
<td>39.5 (19-50)</td>
<td>33.5(11-54)</td>
</tr>
</tbody>
</table>

Medians (range) or number

*All experimental controls included

Primary bronchial epithelial cells included in the study were obtained from Lonza or the NORM and TIP study within the University Medical Center Groningen. COPD patients were included on a basis of FEV₁<50% of predicted, FEV₁/FVC<70% and ≥10 pack-years for GOLD stage IV. All control subjects had FEV₁/FVC>70% and FEV₁>90% of predicted. PBECs obtained from Lonza are not indicated with FEV₁/FVC and FEV₁ predicted nor pack-years.
All participants gave informed consent to a protocol approved by the ethics committee of the Royal Brompton and Harefield NHS Trust/National Heart and Lung Institute and the University Medical Center Groningen. The Section of Respiratory Disease at the University Hospital of Ferrara and the Pneumology Unit at the University Hospital of Messina have ethics committee approval for the collection and analysis of specimens from lung resection surgery.

**Cell culture**

Peripheral blood mononuclear cells (PBMCs) were isolated from whole venous blood by Histopaque (Sigma, Dorset, UK), as previously described (27). Monocytes were isolated from PBMCs by MACS with the Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch-Gladbach, Germany). PBECs were cultured in bronchial epithelium growth medium (BEGM, Lonza) in flasks coated with collagen and fibronectin as described previously (19). Human bronchial epithelial cells (16HBE) were kindly provided by Dr. G. Gruenert and grown in EMEM/10% FCS (UCSF, USA) (18).

**Cell culture and treatments**

Isolated monocytes and human monocyte-macrophage cells (MonoMac6) were cultured in RPMI 1640 GlutaMAX phenol red free media (Invitrogen, Paisley, UK) with 1% FCS, 2mM L-glutamine, 1% nonessential amino acids and 1% sodium pyruvate. Primary monocytes were pre-treated with U0126 (MEK/ERK-1/2 inhibitor), MK-2206 (Akt inhibitor) or IC87114 (PI3K-δ inhibitor) all at 1µM for 30 minutes and were stimulated with H₂O₂ (100µM) for 30 minutes. Primary monocytes were pre-treated with the GSK3β inhibitor CT99021 (100 nM and 1 µM) for 15-120 minutes as indicated. To study the function of glucocorticoids, primary monocytes or transfected MonoMac6 cells were pre-treated with dexamethasone (10nM, 100nM, 1µM) for 30 minutes before being stimulated with LPS (10ng/ml) for 16 hours. Cells or cell-free supernatants were harvested for RNA isolation, cell lysate preparation or measurement of cytokines.

PBECs were cultured for at least 3 weeks and used at passage 3. PBECs and 16HBE cells were passaged by trypsin, plated in 24-well plates and grown to ~90% confluence. Subsequently, PBECs were hormone/growth factor-deprived using basal medium (BEBM, Lonza, Breda, The Netherlands) supplemented with transferrin and insulin (PBECs) and 16HBE were serum-deprived overnight.

PBECs and 16HBE cells were pre-treated with or without 7.5% cigarette smoke extract (CSE) for 6 hours. NAC (5mM) was added 90 min prior to CSE exposure. CT99201 (10µM) was added 30 min prior to CSE treatment for 6 hours or budesonide (1, 10 and 100nM) treatment for 2 hours and cells were subsequently stimulated with TNF-α (10ng/ml) for 24 hours. Cells or cell-free supernatants were harvested for RNA isolation, cell lysate preparation or measurement of cytokines.
**Transfections**

GSK3β on-target siRNA (Dharmacon, Colorado, USA) was used according to the manufacturer’s instructions. The HA-GSK3β-S9A-pcDNA3 and HA-GSK3β-K85A-pcDNA3 expression vectors were kindly provided by Dr. J. Woodget (Toronto, Canada). The following plasmids were obtained from Addgene: plasmid 14754 - GSK3β S9A mutant pcDNA3 (36); Addgene plasmid 14755 - GSK3β K85A mutant pcDNA3.1 or the negative control pcDNA3 construct lacking the GSK3β insert (36).

**Cigarette smoke extract (CSE)**

Two 3R4F research cigarettes (Tobacco Research & Development Center, Lexington, KY) bubbled at 70 rpm through 25 ml EMEM, using a high flow peristaltic pump (Watson Barlow, Rotterdam, the Netherlands) represents 100% CSE. The extract was prepared freshly for each experiment.

**RT-qPCR**

RNA was isolated and HO-1 mRNA expression was analyzed by real-time PCR using Taqman® (Applied Biosystems, Foster City, CA) as described (16). Validated probe and housekeeping genes, β-2-microglobulin (B2M) and peptidylprolyl isomerase A (PP1A) and TaqMan Master Mix were purchased from Applied Biosystems.

**Lung tissue processing and immunohistochemistry**

Lung tissue processing and immunohistochemistry were performed as previously described (44). The anti-p-GSK3β-ser9 (sc-11757-R) and anti-total GSK3β (sc-9166) antibodies were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Biotinylated horse anti-rabbit IgG secondary antibody was used (Vector BA 1000) at 1:200 and staining revealed using a Vectastain ABC kit (Vector, PK-6100) according to the manufacturer’s instructions.

**HDAC2 activity assay**

Cell lysates were prepared and subjected to HDAC immunoprecipitation as previously described (28). Immunoprecipitation was conducted with anti-HDAC2 antibody (Sigma, UK). HDAC activity in the immunoprecipitates was assessed using a fluorometric assay kit (Biovision, Mountain View, CA). Phosphorylated levels of HDAC2 were measured using an anti-p-Ser394-HDAC2 (Abcam, Cambridge, UK).
Western Blot
Whole cell lysates were subjected to western blotting as previously described (28). p-Ser473-Akt, GSK3β, p-GSK3β-ser9, ERK1/2 and p-ERK1/2 antibodies were purchased from Cell Signalling Technology (Herts, UK). Anti-human β-actin was obtained from Santa Cruz Biotechnology and anti-human GAPDH antibody from Abcam (Cambridge, UK).

GM-CSF and CXCL8 cytokine release
Levels of GM-CSF, and CXCL8 were analysed in cell-free supernatants by sandwich ELISA (R&D Systems, Abingdon, UK) according to the manufacturer’s instructions.

Genome wide mRNA expression profile
Monocytes were treated with CT99021 (1 µM), dexamethasone (10⁻⁸ M, 30 min), and LPS (10 ng/ml) as described above and RNA (0.5 µg) was extracted using the RNeasy Mini Kit (Qiagen, Crawley, UK). The mRNA expression profile was determined using the Agilent SurePrint G3 Human microarrays v2 following the manufacturer’s instructions. Differential gene expression was determined using the Partek Genomics Suite using a false discover rate <0.05. Differences > 1.2-fold on mRNA expression were taken into consideration for our analysis. Gene sets significantly enriched in Partek were transferred to the Database for Annotation, Visualisation and Integrated Discovery (DAVID) version 6.7 (http://david.abcc.ncifcrf.gov/). Pathway analysis was performed by Kyoto Encyclopaedia of Genes and Genomes (KEGG).

Statistical analysis
Data were analysed by Friedman or Kruskal-Wallis ANOVA and the Mann-Whitney test to determine statistical significance of non-parametric data. For parametric data, ANOVA and Dunnett’s post-test were used for tests between groups and the student’s t-test was used for tests within groups.
Results

Increased P-GSK3β-ser9 levels in COPD alveolar macrophages, monocytes and bronchial epithelial cells

We first assessed the levels of phosphorylated/inactive GSK3β in peripheral lung tissue, peripheral blood monocytes and PBECs from COPD patients, non-smokers and smokers with normal lung function. Phospho-GSK3β-Ser9 staining was higher in lung tissue macrophages of COPD patients (70.5±4.1% positive) than in control smokers (46.5±6.2, p<0.01) and non-smokers (19.3±3.8, p<0.001) and was also higher in control smokers than non-smokers (Fig. 1a and 1b). The levels of phospho-GSK3β staining were even higher in macrophages (84.9±9.8% positive, p<0.01) from severe COPD compared to moderate COPD patients (Fig. 1b). We were unable to obtain sufficient BAL samples to confirm these results in BAL macrophages using Western blotting. The ratio of phosphorylated to total GSK3β was increased in peripheral blood monocytes from COPD patients compared to healthy subjects with no smoking history as determined by Western blot analysis (0.81±0.17 vs 3.48±0.74, p<0.05)(Fig. 1c). Furthermore, phospho-GSK3β-Ser9 levels were significantly increased in PBECs from COPD stage GOLD IV patients (1.57±0.10, p<0.05) and control smokers (1.57±0.10, p<0.05) compared to non-smoking individuals (1.05±0.05) (Fig. 1d) without significant differences in total GSK3β levels (Fig. 1e). Immunohistochemical staining also indicated strong phospho-GSK3β-Ser9 staining in bronchial epithelium of smokers with and without COPD, although all bronchial epithelial cells in lung tissue stained positive for phospho-GSK3β-Ser9 and we did not detect clear differences compared to non-smoking controls using this method (Fig. 1f). Immunostaining for total GSK3β, detecting both phosphorylated and non-phosphorylated forms, indicated similar, albeit less strong, increases in staining in macrophages from smokers with and without COPD, without a significant difference between these two groups (Figs. 1g, h). All bronchial epithelial cells were stained, and we did not observe differences between the groups (Fig. 1g). Having shown inactivation of GSK3β in different airway cells and blood monocytes in COPD patients, we examined the functional consequences of this altered activation state in monocytes/macrophages and airway epithelial cells.
Effect of GSK3β on glucocorticoid function in COPD

Figure 1. P-GSK3β-ser9 levels are elevated in peripheral lung alveolar macrophages, peripheral blood monocytes and primary bronchial epithelial cells (PBECs) from COPD patients. Representative images (a) and percentage of macrophages (b) positively stained for p-GSK3β-ser9 in peripheral lung sections from non-smokers (n=14), smokers (n=19), mild-moderate COPD (n=21) and severe COPD patients (n=7). Ratio of p-GSK3β/total GSK3β in primary monocytes (n=6-10) with representative blots (c) and p-GSK3β/GAPDH (d) and total GSK3β/GAPDH (e) with representative blots in PBECs from non-smokers, smokers and GOLD stage IV COPD patients (n=7-8). Representative images of staining of p-GSK3β in large airway epithelial cells in peripheral lung sections from non-smokers, smokers and COPD patients are shown beneath (f) along with an isotype-stained section as a control. (g) Total GSK3β staining in macrophages of COPD subjects and controls. (h) Percentage of GSK3β-positive macrophages. *p<0.05 and **p<0.01 as tested by Kruskal-Wallis ANOVA.

GSK3β inhibition abrogates glucocorticoid responsiveness in primary human blood monocytes

We next investigated whether GSK3β inactivation affects the regulation of inflammatory cytokines. Treatment of monocytes from healthy subjects with the selective GSK3β inhibitor CT99021 had no effect on basal GM-CSF and CXCL8 release, nor on the release upon treatment with the pro-inflammatory stimulus LPS (Fig. 2a and 2b).

Previously, we showed that the glucocorticoid dexamethasone was less effective at repressing LPS-induced GM-CSF and CXCL8 release in blood monocytes from patients with COPD compared with age-matched smokers (27). Therefore, we also investigated the effect of GSK3β inactivation on glucocorticoid responsiveness upon LPS stimulation in monocytes. Of interest, dexamethasone (10nM) dependent inhibition of LPS-induced GM-CSF (63.9±6.7%, p<0.05) and CXCL8 (24.42±6.5%, p<0.05) release was completely abrogated by CT99021 (Fig. 2c and 2d).

Oxidative stress induces PI3K/Akt-dependent inhibition of GSK3β activity in monocytes

Because of our hypothesis that oxidative stress induces glucocorticoid responsiveness, we next examined how GSK3β activity is modulated in response to exogenous reactive oxygen species (ROS) in primary monocytes, as both hydrogen peroxide (H₂O₂) and cigarette smoke extract (CSE) exposure reduce glucocorticoid sensitivity in monocytes (7, 30, 31). H₂O₂ increased phospho-GSK3β-ser9 levels in a time-dependent manner (Fig. 3a). Exposure to H₂O₂ also activated PI3K as measured by increased levels of phospho-Akt-Ser473, at earlier time points than GSK3β-ser9 phosphorylation (Fig. 3a). Inhibition of Akt (MK-2206) reversed the oxidant-induced inactivation of GSK3β (Fig. 3b). Similarly, GSK3β phosphorylation was reduced by the MEK/ERK-1/2 inhibitor U0126, indicating involvement of the ERK1/2 pathway in the oxidant-induced effect on GSK3β in primary monocytes (Fig. 3a and 3b). We previously showed that PI3Kδ is responsible for the oxidant-induced activation of Akt in monocytes (27). However, selective inhibition of PI3Kδ with IC87114 did not affect oxidant
induction of phospho-GSK3β-ser9 in monocytes (Fig. 3b), indicating involvement of other PI3K isoforms or signaling mediators.

Figure 2. GSK3β inhibition attenuates the anti-inflammatory action of glucocorticoids in monocytes. CT99021 does not affect baseline or LPS-induced GM-CSF or CXCL8 secretion in primary monocytes from non-COPD individuals. GM-CSF (a) and CXCL8 (b) levels were measured in supernatants of primary monocytes upon pre-treatment with CT99021 for 30 minutes followed by 24 hours of LPS. Treatment of monocytes isolated from healthy subjects with CT99021 inhibits dexamethasone-induced suppression of LPS-stimulated (c) GM-CSF and (d) CXCL8 release (mean±SEM, n=6-7). P values are indicated.

GSK3β protein knockdown and overexpression of inactive GSK3β reduces glucocorticoid function in monocytes

To gain further mechanistic insight in the role of GSK3β in oxidant-induced glucocorticoid unresponsiveness in monocytes, we used siRNA to knock-down total GSK3β levels and analyse the anti-inflammatory actions of dexamethasone. Transfection of MonoMac6 cells with GSK3β on-target siRNA significantly reduced GSK3β total protein levels compared with scrambled control siRNA (Fig. 4a). In line with the CT99021 effect, knockdown of GSK3β significantly inhibited the ability of dexamethasone to suppress CXCL8 expression, and the dexamethasone EC<sub>50</sub> was increased from 22 to 100nM. In addition, the inhibitory effect of dexamethasone on LPS-stimulated CXCL8 expression was decreased from 52.5±4.8% to 75.8±7.1% (Fig. 4b, left panel). Similar effects were seen with GSK3β knockdown on the dexamethasone suppression of LPS-induced GM-CSF secretion (Fig. 4b, right panel).
Chapter 3

Effect of GSK3β on glucocorticoid function in COPD

Figure 3. Oxidative stress induced inactivation of GSK3β is mediated via PI3K/Akt in primary monocytes.
(a) Primary monocytes from non-COPD individuals were exposed to H2O2, which time-dependent increase in PI3K, ERK1/2 and GSK3β phosphorylation as detected by western blotting. Representative blots of 4 independent experiments are shown. (b) GSK3β phosphorylation is PI3K/Akt and ERK1/2-dependent in monocytes as indicated by pre-treatment of the cells with MEK/ERK-1/2 inhibitor U0126, the Akt inhibitor MK-2206 and PI3Kδ inhibitor IC87114. Densitometry was performed and phospho-ser9-GSK3β levels are expressed as ratio of total GSK3β (mean±SEM, n=5).

To validate our findings, we overexpressed the K85A kinase dead GSK3β mutant and analysed dexamethasone function. MonoMac6 and primary cells produce similar levels of inflammatory mediators following stimulation with LPS (Fig. 4c, left panel). Dexamethasone significantly reduced LPS-induced GM-CSF release by 33.1±2.8% in MonoMac6 cells transfected with the control pcDNA3.1. Dexamethasone had no significant inhibitory effect on LPS-induced GM-CSF release when the K85A GSK3β mutant was overexpressed (91.3±12.2% versus 111.4±15.5%, Fig. 4c).
Figure 4. GSK3β modulates dexamethasone function in MonoMac6 cells. (a) GSK3β levels are reduced by GSK3β siRNA after 24 hours of transfection. Densitometry was performed and GSK3β levels are expressed as ratio of β-actin as loading control. (b) GSK3β siRNA knock-down (24 hours) inhibits the concentration-dependent suppression of LPS-induced CXCL8 (left panel) and GM-CSF (right panel) release by dexamethasone (mean±SEM, n=6). (c) LPS-induced GM-CSF release in mock transfected monocytes and cells transfected with the positive control pcDNA3.1 (pg/ml, mean±SEM, n=4), and effect of overexpression of the inactive mutant GSK3βK85A on dexamethasone suppression of LPS-induced GM-CSF release (% mean±SEM, n=4). (d) Overexpression of the constitutively active GSK3βS9A mutant restores H2O2-induced dexamethasone unresponsiveness of GM-CSF release (mean±SEM, n=4).
To confirm that GSK3β mediates oxidant-induced glucocorticoid insensitivity in monocytes, we overexpressed a constitutively active S9A GSK3β mutant in MonoMac6 cells and analysed dexamethasone function during H$_2$O$_2$ exposure. In line with previous studies (27), the anti-inflammatory effect of dexamethasone was significantly attenuated by H$_2$O$_2$ pre-treatment (Fig. 4d). In the presence of the active S9A mutant, H$_2$O$_2$-induced dexamethasone insensitivity was suppressed, leading to a significant (27.2±1.3%) inhibition of LPS-stimulated GM-CSF release, similar to that observed in control cells (26.7±2.5% inhibition, Fig. 4d).

**GSK3β-regulated glucocorticoid responsiveness is HDAC2-dependent in human monocytes**

Since HDAC2 has been implicated in oxidative stress-induced glucocorticoid unresponsiveness (4), we investigated whether ROS-induced inactivation of GSK3β may lead to modulation of HDAC2 activity in primary monocytes. Inhibition of GSK3β activity by treatment with CT99021 reduced the activity of immunoprecipitated HDAC2 (Fig. 5a). This reduction in HDAC2 activity correlated with increased phosphorylation of ser394 (Fig. 5b), while HDAC2 mRNA and protein levels were not affected by GSK3β inactivation (data not shown).

**Effect of GSK3β inhibition on dexamethasone-regulated inflammatory gene expression in human monocytes**

We also investigated the effect of CT99021 on dexamethasone regulation of LPS-induced gene expression using gene arrays. Partek analysis identified 17 genes that were differentially expressed (FDR <0.05) upon CT99021 exposure. CT99021 specifically affected genes involved in the Wnt/β-catenin signalling pathway ($P$=0.05) in LPS-stimulated MonoMac6 cells (data not shown), thereby confirming the specificity of CT99021 action. We next investigated the effect of CT99021 on LPS/dexamethasone-treated monocytes. 164 known genes were differentially expressed upon GSK3β inhibition in the presence of LPS/dexamethasone ($P$<0.05). KEGG analysis showed key pathways that these genes regulate (Table 5). 13 out of the 164 genes encode for inflammatory chemokines (such as CXCL6, CXCL3, CXCL2 and CXCL1), cytokines (such as GM-CSF, G-CSF) and cytokine/chemokine receptors involved in the cytokine-cytokine receptor interaction pathway ($P$=2.4×10⁻³). 10 more genes encode for proteins involved in chemokine signalling pathways ($P$=2×10⁻⁴) and 7 genes encode for proteins that regulate the neuro-active receptor-ligand interaction ($P$=6.5×10⁻²).
Figure 5. GSK3β-regulated glucocorticoid function is HDAC2-dependent in monocytes. (a) Treatment of primary monocytes with CT99021 inhibits the enzymatic activity of HDAC2 (mean±SEM, n=4) (b) CT99021 treatment induces p-HDAC2-ser394 in primary monocytes. Densitometry was performed and phospho-HDAC2 levels are expressed as ratio of total HDAC (mean±SEM, n=4).

Table 5. Pathways affected by differential gene expression in response to CT99021 treatment in MonoMac6 cells.

<table>
<thead>
<tr>
<th>Category</th>
<th>Term</th>
<th>Genes (out of 164)</th>
<th>% of total number genes</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEGG_PATHWAY</td>
<td>Cytokine-cytokine receptor interaction</td>
<td>13</td>
<td>7.9%</td>
<td>2.4E-5</td>
</tr>
<tr>
<td>KEGG_PATHWAY</td>
<td>Chemokine signaling pathway</td>
<td>10</td>
<td>6.1%</td>
<td>2.0E-4</td>
</tr>
<tr>
<td>KEGG_PATHWAY</td>
<td>Neuroactive ligand-receptor interaction</td>
<td>7</td>
<td>4.2%</td>
<td>6.5E-2</td>
</tr>
</tbody>
</table>

KEGG analysis showed 164 known genes that were differentially expressed due to GSK3β inhibition in the presence of LPS/dexamethasone. 13 out of the 164 genes encode for inflammatory chemokines. 10 genes encode for proteins involved in chemokine signalling pathways and 7 genes encode for proteins that regulate the neuroactive receptor-ligand interaction.
GSK3β inhibition abrogates glucocorticoid responsiveness in primary human bronchial epithelial cells
We previously reported that TNF-α-induced GM-CSF production in PBECs from GOLD stage II COPD patients was less responsive to the clinically used inhaled glucocorticoid budesonide compared to non-smoking controls, with an intermediate effect of budesonide in PBECs from control smokers (16). In a similar manner to monocytes, CT99021 had no effect on GM-CSF and CXCL8 release in PBECs from non-COPD individuals at baseline or upon stimulation with TNF-α, a relevant mediator of inflammation in COPD (Fig. 6a and 6b). In further line with our findings in monocytes, pre-treatment of PBECs from non-COPD individuals with CT99021 resulted in complete abrogation of the anti-inflammatory effect of budesonide on TNF-α-stimulated GM-CSF and CXCL8 release (Fig. 6c and 6d).

Oxidative stress leads to reduced glucocorticoid responsiveness, activation of the PI3K/Akt pathway and inhibition of GSK3β activity in bronchial epithelial cells
Because of the limited cell numbers of primary cultures, further mechanistic studies were performed in the human bronchial cell line 16HBE. Bronchial epithelial cells are in direct contact with inhaled cigarette smoke, which known to induce oxidative stress in these cells (4, 33, 41). Therefore, we studied the effect of CSE, which is known to exert similar effects in 16HBE and PBECs at least in part through oxidative stress mechanisms (18). Exposure of 16HBE cells to CSE (7.5%) for 6 hours led to a significant up-regulation of heme-oxygenase-1 (HO-1) mRNA, a marker of oxidative stress, which was blocked by the oxidant scavenger N-acetyl-cysteine (NAC), confirming that CSE exposure induces oxidative stress in epithelial cells (data not shown). In addition, CSE exposure reduced the ability of budesonide to suppress TNF-α-induced CXCL8 release (Fig. 7a and 7b), which was reversed by NAC, confirming the involvement of oxidative stress (Fig. 7c). Similar to the effects of oxidative stress in monocytes, CSE (7.5%) induced activation of PI3K/Akt signaling and inactivation of GSK3β in 16HBE, which was also reversed by NAC although this did not reach significance (p=0.0692)(Fig. 7d). Together, our data show that CSE-derived ROS result in GSK3β inactivation in bronchial epithelial cells and that GSK3β inhibition reduces glucocorticoid sensitivity of pro-inflammatory responses in both human monocytes and bronchial epithelial cells.
Figure 6. GSK3β inhibition attenuates the anti-inflammatory action of glucocorticoids in primary bronchial epithelial cells (PBECs). CT99021 does not affect GM-CSF or CXCL8 secretion in PBECs. GM-CSF (a) and CXCL8 (b) levels were measured in cell-free supernatants of PBECs from non-COPD individuals upon pre-treatment with CT99021 for 30 minutes followed by 24 hours TNF-α stimulation of PBECs (mean±SEM, n=4-6). Pre-treatment with CT99021 (30 min) reverses budesonide (Bud)-induced suppression of TNF-α-stimulated GM-CSF (c) and CXCL8 (d) release in PBECs from non-COPD individuals (mean±SEM, n=8).
Figure 7. Cigarette smoke extract (CSE)-induced oxidative stress induces budesonide unresponsiveness in TNF-α-stimulated 16HBE cells. (a, b, c) Pre-treatment with CSE reduces budesonide (Bud)-induced suppression of TNF-α-stimulated CXCL8 release and pre-treatment with NAC (30 min) restores CSE-induced budesonide unresponsiveness (mean±SEM, n=5). Absolute values (a), values related to the TNF-α-induced control (b) and percent inhibition by budesonide (c) are shown (d) CSE induces PI3K and GSK3β phosphorylation of cells, as indicated by Western blotting. Representative of 3 independent experiments are shown. The CSE-induced increase in GSK3β phosphorylation is abrogated by NAC pre-treatment. Densitometry was performed and phospho-ser9-GSK3β levels are expressed as ratio of GAPDH as loading control (mean±SEM, n=6).
Together, our data indicate that GSK3β inhibition reduces glucocorticoid sensitivity of pro-inflammatory responses in both human monocytes and bronchial epithelial cells without modulating inflammatory mediator expression *per se*. The mechanism for the effect differs between cell types.

**Discussion**

The increased oxidant burden derived from cigarette smoking in the lungs of COPD patients has been associated with reduced glucocorticoid responsiveness. The molecular mechanisms of oxidative stress-induced glucocorticoid unresponsiveness have remained unknown to date. Our data show, for the first time, that levels of inactive phosphorylated GSK3β are higher in lung macrophages, peripheral blood monocytes and bronchial epithelial cells from COPD patients compared to control subjects. In both monocytes and bronchial epithelial cells, pharmacological inactivation of GSK3β resulted in reduced responsiveness of inflammatory mediators to glucocorticoids. We observed a difference in glucocorticoid insensitivity between non-smoking controls and COPD patients, but not between current smokers and COPD patients or current smokers and healthy controls. This indicates that smokers have an intermediate state of sensitivity, and that individuals with COPD are more susceptible to develop steroid insensitivity upon smoking. Furthermore, we previously observed more pronounced glucocorticoid unresponsiveness in epithelial cells from severe compared to moderate COPD patients (16). Because severe COPD patients are dependent on the use of inhaled or oral glucocorticoids, it is of importance to elucidate the mechanisms of glucocorticoid unresponsiveness in COPD order to improve the treatment of patients with severe symptoms.

Since we observed that phospho-GSK3 levels were still increased in PBECs from severe, ex-smoking COPD patients, even after 2-3 weeks of culture, we anticipate that there may be persistent alterations in the regulators of GSK3 phosphorylation, resulting from rewiring of the intracellular inflammatory pathways rather than an effect of recent exposure to the local inflammatory milieu in the COPD lung. The antibody used to detect GSK3β also detects GSK3α, thus although we cannot discount a role of GSK3α here, they have identical functions. With respect to therapeutic intervention, it will be important to further elucidate the downstream mechanisms involved in the reduced glucocorticoid responsiveness upon GSK3β inactivation. GSK3β is involved in numerous intracellular pathways, and preventing its inactivation, e.g. by pharmacological inhibition of the PI3K/Akt or MAPK pathways, may lead to serious side effects.

In line with our results, the activation of GSK3β has been previously implicated in glucocorticoid-induced apoptosis in lymphoma cells, its inactivation resulting in glucocorticoid resistance, although effects on inflammatory responses were not studied.
(35). In monocytes, GSK3β inactivation reduced glucocorticoid suppression of pro-inflammatory responses by inhibition of the enzymatic activity of HDAC2. This reduction in activity was not associated with a change in expression but an increase in HDAC2 phosphorylation at serine 394. Casein kinase 2 (CK2) phosphorylates HDAC2 at ser394 and is a direct target of GSK3β, negatively regulating its function (38). Therefore, inactivation of GSK3β in monocyte-macrophages may increase CK2-induced phosphorylation of HDAC2. This may be involved in the observed glucocorticoid unresponsiveness towards NF-κB-induced pro-inflammatory cytokine production upon GSK3β inactivation in monocytes/macrophages. Although the functions of individual HDAC2 phosphorylation sites and the responsible kinases are unclear, the activity of this important GRα co-repressor may deprive GRα of a key mechanism by which to control inflammatory gene expression.

In line with our findings in monocytes, our data indicate that glucocorticoid unresponsiveness is induced upon GSK3β inactivation in airway epithelial cells, and that cigarette smoke-induced oxidative stress may be responsible for this effect. Our combined data from monocytes and epithelial cells suggest that GSK3β may be an important common redox sensing effector molecule for a number of signalling pathways including MEK/ERK-1/2 and PI3K/Akt, regulating NF-κB activation and the subsequent inflammatory mediator release and inflammatory cell recruitment (12, 29). These redox sensitive p38 MAPK, ERK-1/2 and PI3K/Akt pathways can all induce GSK3β phosphorylation (8,(15) and have been implicated in glucocorticoid insensitivity in COPD (5). This further corroborates the role of GSK3β in oxidative stress-induced glucocorticoid unresponsiveness.

The monocyte microarray data show that the anti-inflammatory effects of dexamethasone are prevented in the presence of CT99021. Not surprisingly, therefore, the effect of GSK3β inhibition on enhancing the expression of LPS-induced inflammatory genes was more marked in the presence of dexamethasone. These genes, mostly chemokines and cytokines, regulate signalling pathways that induce neutrophil, lymphocyte and macrophage activation indicating that GSK3β activity is important for regulating multiple inflammatory pathways modulated by glucocorticoids. This supports our hypothesis that aberrant GSK3β activity is involved in driving chronic inflammation through enhancing glucocorticoid insensitivity in COPD.

GSK3β inhibition also resulted in significant hits in the neuropeptide/neurotransmitter receptor interacting pathways, including those for the 5-hydroxytryptamine (5-HT) receptors 2b and 6 (HTR2b and HTR6), the protease-activated receptor (PAR) family, galanin receptor 2 (Glar2), the glutamate receptor delta 2 (Grid2) and GABA B receptors 1 and 2. The neurotransmitter serotonin (5-HT) is also released from the neuroendocrine cells of the human lung, increasingly recognized for their immunomodulatory effects outside the CNS and contributing to the pathogenesis of autoimmune and chronic inflammatory diseases (40). The serum concentration of the tryptophan, the amino acid precursor of the
5-HT is increased in patients with COPD (42), whereas plasma 5HT levels are elevated in smokers with normal lung function but reduced in COPD patients (39). In addition, cigarette smoke affects airway hyper-responsiveness through 5-HT in precision-cut lung slices (11). Finally, recent evidence indicates that 5-HT suppresses efferocytosis in human alveolar macrophages, although this appears to be independent of HTR2B (40). COPD patients have higher maximum thrombin levels, rates of thrombin generation and total thrombin formation although this was not linked to severity or inflammatory mediator expression (43). PAR-1 is activated by the thrombin and it is overexpressed in the alveolar macrophages from smokers with normal lung function (34). PAR-4 is activated by thrombin and trypsin. PAR-4 methylation and altered expression may be important in the enhanced risks associated with cigarette smoking that continue even after cessation (45). GABA is produced by the bronchial epithelium and contributes to the relaxation of airway smooth muscle tone (14). GABA A receptors are known to be expressed on bronchial epithelial cells, mediating mucus production in response to nicotine (13), while the loss of GABA B receptors modifies the biochemical and behavioral responses to nicotine withdrawal (2). However, the function of GABA B receptors in the human airways and in COPD patients is unknown. It is increasingly evident that there are neural-like transmitter interactions in human bronchial epithelial cells which may link CNS-active drugs to the increased inflammation and mucin production seen in COPD.

Taken together, our study shows that reduced GSK3β activity in COPD monocytes-macrophages and airway epithelial cells may contribute to cigarette smoke-induced glucocorticoid insensitivity in the airways of COPD patients. The key nodal function of GSK3β in integrating various ROS-induced upstream and downstream signalling pathways in different cell types suggests that reversing this inactivation may constitute a novel therapeutic strategy to improve glucocorticoid function and thereby suppress airway inflammation in COPD.

**Acknowledgements**

This research was partially performed within the framework of the Top Institute Pharma project T1-201 “COPD, transition of systemic inflammation into multi-organ pathology”, with partners University Medical Center Groningen, University Medical Center Utrecht, University Medical Center Maastricht, Nycomed BV, GlaxoSmithKline, Danone, AstraZeneca, and Foundation TI Pharma. This project was supported by the NIHR respiratory Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation and Imperial College London. AN is the recipient of a BBSRC CASE award with Pfizer. IMA and PJB are supported by a Wellcome Trust programme grant and through COPD-MAP. GC is supported by unrestricted educational grants from AstraZeneca Italy, Boehringer Ingelheim Italy, GSK Italy and Menarini.
References


